Business Nasal spray for paroxysmal supraventricular tachycardia enters US market February 3, 2026 11:10 am Cardiovascular Business 0 Min Read SHARE New drug allows patients to self-treat PSVT. About 2 million people in the U.S. have been diagnosed with condition. This post was originally published on this site Previous Article San Francisco small businesses impacted by outages announce lawsuit against PG&E Next Article San Francisco Small Businesses to Sue PG&E Over Losses From December Power Outages
